[D-p-Cl-Phe6, Leu17]-VIP (TFA)

[D-p-Cl-Phe6, Leu17]-VIP TFA is a competitive and selective antagonist of vasoactive intestinal peptide (VIP) receptor, with the IC50 of 125.8 nM. [D-p-Cl-Phe6, Leu17]-VIP TFA has no activity on glucagon, secretin or GRF receptors[1][2][3].

Product Specifications

UNSPSC

12352209

Target

PACAP Receptor

Type

Peptides

Related Pathways

GPCR/G Protein

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/d-p-cl-phe6-leu17-vip-tfa.html

Purity

98.16

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

OC(C(F)(F)F)=O.OC(C=C1)=CC=C1C[C@@H](C(N[C@@H](CC(C)C)C(N[C@@H](CC(N)=O)C(N[C@@H](CO)C(N[C@@H]([C@@H](C)CC)C(N[C@@H](CC(C)C)C(N[C@H](C(N)=O)CC(N)=O)=O)=O)=O)=O)=O)=O)NC([C@H](CCCCN)NC([C@H](CCCCN)NC([C@H](C(C)C)NC([C@H](C)NC([C@H](CC(C)C)NC([C@H](CCC(N)=O)NC([C@H](CCCCN)NC([C@H](CCCNC(N)=N)NC([C@H](CC(C)C)NC([C@H](CCCNC(N)=N)NC([C@H]([C@H](O)C)NC([C@@H](NC([C@H](CC(N)=O)NC([C@H](CC(O)=O)NC([C@H]([C@H](O)C)NC([C@H](NC([C@H](C(C)C)NC([C@H](C)NC([C@H](CC(O)=O)NC([C@H](CO)NC([C@@H](N)CC2=CN=CN2)=O)=O)=O)=O)=O)CC3=CC=C(C=C3)Cl)=O)=O)=O)=O)CC4=CC=C(C=C4)O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O

Molecular Formula

C150H240F3ClN44O44

Molecular Weight

3456.22

References & Citations

[1]Pozo D, et, al. Characterization of VIP receptor-effector system antagonists in rat and mouse peritoneal macrophages. Eur J Pharmacol. 1997 Mar 5; 321 (3) : 379-86.|[2]Pandol SJ, et, al. Vasoactive intestinal peptide receptor antagonist [4Cl-D-Phe6, Leu17] VIP. Am J Physiol. 1986 Apr; 250 (4 Pt 1) : G553-7.|[3]Messmer B, et, al. Regulation of exocrine pancreatic secretion by cerebral TRH and CGRP: role of VIP, muscarinic, and adrenergic pathways. Am J Physiol. 1993 Feb; 264 (2 Pt 1) : G237-42.